+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statins and stroke prevention

Statins and stroke prevention

Cerebrovascular Diseases 24(2-3): 170-182

Over the past decade, statins have been proven to significantly decrease coronary events in primary and secondary prevention of coronary artery disease. Recent clinical trials have indicated that statins significantly reduce stroke risk in patients with vascular disease. The Cholesterol Treatment Trialists' Collaborators in a meta-analysis including 90,056 patients found that the use of statins determined a significant 17% proportional reduction in the incidence of first-ever stroke of any type per 1 mmol/l low-density lipoprotein (LDL) cholesterol reduction. During an average of 5 years of treatment, the reduction in the overall incidence of stroke was about one sixth per 1 mmol/l LDL cholesterol decrease meaning that 8 fewer participants have any stroke per 1,000 among those with preexisting coronary artery disease at baseline, compared with 5 fewer per 1,000 among the participants with no such history. It is not known whether these findings might be due to the cholesterol reduction effect of statins or to pleiotropic effects of statins, such as improved endothelial function, decreased platelet aggregability, and reduced vascular inflammation. In secondary prevention of stroke, the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study found that treatment with atorvastatin reduced the risk of recurrent cerebrovascular events in patients with recent stroke or transient ischemic attack but no history of heart disease. Combining the results of patients with no history of heart disease from the SPARCL study and Heart Protection Study in a mini meta-analysis, compared with placebo, statins were associated with a barely nonsignificant difference in recurrent stroke (OR = 0.87, 95% CI = 0.75-1.01, p = 0.07) and a significant difference in the occurrence of major vascular events (OR = 0.78, 95% CI = 0.68-0.88, p = 0.0001) at final follow-up.

(PDF emailed within 0-6 h: $19.90)

Accession: 055911862

Download citation: RISBibTeXText

PMID: 17596685

DOI: 10.1159/000104474

Related references

Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet. Neurology 8(5): 453-463, 2009

3 steps to stroke prevention and stroke recovery. Drink tea, take statins, and change negative lifestyle habits--even just one--to aid stroke risk reduction and recovery. Dukemedicine Healthnews 15(5): 4-5, 2009

Application of Digital Diagnosis and Treatment Technique in Benign Mandibular Diseases. Journal of Craniofacial Surgery, 2018

Impacts of stroke clinics on the utilization of statins for secondary prevention of ischemic stroke. Zhonghua Nei Ke Za Zhi 49(7): 595-598, 2011

HMG CoA reductase inhibitors (statins): use in stroke prevention and outcome after stroke. Expert Review of Neurotherapeutics 4(2): 241-247, 2005

Stroke, cholesterol and statins--are there new data about stroke prevention?. Deutsche Medizinische Wochenschrift 126(22): 664-670, 2001

Statins for stroke prevention. Current Atherosclerosis Reports 9(4): 305-311, 2008

Statins and stroke prevention. Expert Review of Cardiovascular Therapy 7(10): 1231-1243, 2010

Statins and prevention of stroke. Tidsskrift for den Norske Laegeforening 125(10): 1385-6; Author Reply 1386, 2005

Statins and stroke: prevention and beyond. Current Opinion in Neurology 24(1): 75-80, 2011

Statins for prevention of stroke?. Duodecim; Laaketieteellinen Aikakauskirja 115(12): 1277-1278, 2002

Stroke prevention by statins. Nihon Rinsho. Japanese Journal of Clinical Medicine 60(5): 993-1001, 2002

Statins in stroke prevention. Anadolu Kardiyoloji Dergisi 8(3): 217-222, 2008

Statins in stroke prevention: what an internist should know. European Journal of Internal Medicine 19(1): 8-14, 2008

Statins for the prevention of first or recurrent stroke. Current Vascular Pharmacology 6(2): 124-133, 2008